FIELD: medicine.
SUBSTANCE: claimed is method of postnatal DNA-diagnostics of mucoviscidosis. 14 most significant mutations 1677delTA, W1282X (R), 2143delT, G542X, R553X, G551D, 2184InsA, N1303K, 394DelTT, R334W, R347P, CFTR del21kb, delF508 in gene of mucoviscidosis CFTR are analysed. Method includes multiplex amplification of gene mutation populations in clinical sample of DNA by two-stage nested polymerase chain reaction (PCR) with application of selected set of primers.
EFFECT: invention makes it possible to diagnose presence of mucoviscidosis with high accuracy, due to simultaneous analysis of several mutations at a time.
4 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR IDENTIFYING MUCOVISCIDOSIS CAUSING MUTATIONS IN CFTR HUMAN GENE, KIT OF PRIMERS, BIOCHIP, KIT OF TARGETS AND TEST SYSTEMS USED IN METHOD | 2012 |
|
RU2529717C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES MEDIATED BY CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | 2015 |
|
RU2744460C2 |
| METHOD OF PRENATAL AND POSTNATAL DNA-DIAGNOSTICS OF DOWN, EDWARDS PATAU SYNDROME MUTATION delF508 IN GENE OF MUCOVISCIDOSIS AND RHESUS-FACTOR OF FOETUS | 2014 |
|
RU2539778C1 |
| METHOD OF SCREENING NEWBORNS FOR MONOGENIC DISEASES AND BIOCHIP FOR SAID METHOD REALISATION | 2008 |
|
RU2402612C2 |
| METHOD FOR PRE-IMPLANTATION GENETIC TESTING OF CYSTIC FIBROSIS | 2021 |
|
RU2777078C1 |
| METHOD FOR PREDICTING CARDIO-VASCULAR DISEASES AND DIAGNOSTIC KIT FOR ITS IMPLEMENTATION | 2005 |
|
RU2304775C2 |
| METHOD OF DETERMINING PHYSICAL CAPABILITY OF HUMAN BEING | 2008 |
|
RU2414511C2 |
| SET OF OLIGONUCLEOTIDE PROBES, DNA-MICROCHIP, METHOD OF ITS OBTAINING, SET FOR MOLECULAR-GENETIC RESEARCH OF HUMAN AND THEIR APPLICATION | 2013 |
|
RU2551985C2 |
| HIGH-PERFORMANCE TEST HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD | 2015 |
|
RU2691136C2 |
| METHOD FOR GENETIC MARKER PREDICTION OF RISK OF GESTOSIS | 2010 |
|
RU2431842C1 |
